# Standard Biotools Inc.: Form 10-K for the period ended Dec 31, 2013

- Company: [Standard Biotools Inc.](/companies/lab.md) (CIK 1162194)
- Form: 10-K
- Filed: 2014-03-12
- Accepted by EDGAR: Mar 12, 2014, 17:00 ET
- Period: 2013-12-31
- Accession: 0001162194-14-000010
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1162194/000116219414000010/fye2013form10-k.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1162194/000116219414000010/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2013-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2013-10-01 to 2013-12-31 | $20.9m | us-gaap:Revenues |
| Revenue | 12 months, 2013-01-01 to 2013-12-31 | $71.2m | us-gaap:Revenues |
| Cost of revenue | 12 months, 2013-01-01 to 2013-12-31 | $300.0k | us-gaap:CostOfRevenue |
| Research and development | 12 months, 2013-01-01 to 2013-12-31 | $20.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months, 2013-01-01 to 2013-12-31 | $48.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months, 2013-01-01 to 2013-12-31 | −$18.7m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months, 2013-01-01 to 2013-12-31 | $14.0k | us-gaap:InterestExpense |
| Income tax | 12 months, 2013-01-01 to 2013-12-31 | $137.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months, 2013-01-01 to 2013-12-31 | −$16.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2013-10-01 to 2013-12-31 | −$0.18 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 12 months, 2013-01-01 to 2013-12-31 | −$0.65 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 12 months, 2013-01-01 to 2013-12-31 | −$1.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months, 2013-01-01 to 2013-12-31 | $3.4m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2013-12-31 | $35.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2013-12-31 | $104.6m | us-gaap:AssetsCurrent |
| Total assets | at 2013-12-31 | $116.9m | us-gaap:Assets |
| Current liabilities | at 2013-12-31 | $18.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2013-12-31 | $20.5m | us-gaap:Liabilities |
| Shareholders' equity | at 2013-12-31 | $96.4m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1162194/000116219414000010/fye2013form10-k.htm

Filed Mar 12, 2014.
Source: SEC EDGAR, the filing index for accession 0001162194-14-000010. Last ingested by Listed: Nov 5, 2026, 21:16 ET. No prices; not investment advice.
